Login to Your Account

Pharma: Clinic Roundup

Wednesday, November 6, 2013
• Shire plc, of Dublin, reported positive top-line results from two identically designed randomized placebo-controlled Phase III studies evaluating the efficacy and safety of Vyvanse (lisdexamfetamine dimesylate) capsules (CII) vs. placebo in adults with binge eating disorder (BED).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription